Voriconazole is a second-generation triazole antifungal that has become the preferred drug for treating aspergillosis in many avian species. It offers broader antifungal activity and improved tissue penetration compared to first-generation azoles like itraconazole. Originally developed for human medicine, voriconazole has been increasingly adopted by avian veterinarians due to its superior efficacy against Aspergillus species. This is a prescription medication that requires careful veterinary oversight, particularly because pharmacokinetics vary dramatically between bird species.
What Is Voriconazole Used For?
- Aspergillosis — the primary indication in avian medicine; aspergillosis is caused by Aspergillus fumigatus and related species and is one of the most common and lethal fungal infections in captive and wild birds
- Invasive fungal infections — disseminated mycoses that have spread beyond the respiratory tract
- Prophylaxis — preventive treatment in immunocompromised birds or those in high-risk environments (e.g., rehabilitation centers, zoological collections)
Aspergillosis in birds affects the respiratory system, including the lungs, air sacs, and syrinx (voice box). Because birds lack a diaphragm and rely on air sacs for respiration, fungal plaques in these structures can be rapidly fatal. Voriconazole’s excellent penetration into respiratory tissue makes it particularly valuable.
How Does Voriconazole Work?
Like other azole antifungals, voriconazole inhibits the cytochrome P-450-dependent enzyme 14-alpha-lanosterol demethylase, which is essential for converting lanosterol to ergosterol in the fungal cell membrane. Without ergosterol, the cell membrane loses integrity, leading to leakage of cellular contents and fungal death. Voriconazole has enhanced affinity for the Aspergillus target enzyme compared to older azoles, explaining its superior clinical activity against aspergillosis.
Voriconazole also demonstrates activity against Candida species, Scedosporium, Fusarium, and other opportunistic fungi that may occasionally affect avian patients.
Dosage
Dosing is highly species-dependent and must be determined by an experienced avian veterinarian.
| Avian Group | Typical Dose | Route | Frequency |
|---|---|---|---|
| Psittacines (parrots) | 10—12 mg/kg | Oral | Every 12 hours |
| Raptors (most species) | 10—12 mg/kg | Oral | Every 8—12 hours |
| Waterfowl | 10—20 mg/kg | Oral | Every 8—12 hours |
| Penguins | CONTRAINDICATED | — | — |
Critical species variations: Pharmacokinetic studies have revealed enormous differences in how various bird species metabolize voriconazole. Some species (such as African penguins) are extremely sensitive and can develop fatal toxicity at standard doses. Other species (such as some chickens and pigeons) metabolize the drug so rapidly that therapeutic levels are difficult to achieve.
Voriconazole is typically administered as an oral suspension, compounded from tablets or commercial powder. Intravenous formulations are available for critical cases. Treatment duration for aspergillosis is prolonged, typically 4 to 12 weeks or longer, continuing well beyond resolution of clinical signs.
Side Effects
Common side effects include:
- Mild gastrointestinal upset
- Transient visual disturbances (reported in humans; difficult to assess in birds)
- Mild lethargy during initial treatment
Serious side effects requiring immediate veterinary attention:
- Hepatotoxicity — elevated liver enzymes progressing to liver failure; monitor with regular blood work
- Neurotoxicity — ataxia, seizures, blindness, or abnormal behavior; more common in sensitive species or at high doses
- Skin photosensitivity — reported in humans with prolonged use
- Cardiac effects — QT prolongation at high plasma concentrations
In birds, early signs of toxicity include lethargy, inappetence, ataxia (loss of balance), and changes in droppings. Any neurological signs warrant immediate discontinuation and veterinary contact.
Therapeutic Drug Monitoring
Therapeutic drug monitoring (TDM) is strongly recommended when using voriconazole in avian patients. Target trough plasma concentrations are generally considered to be 1 to 5 micrograms/mL, though optimal ranges may vary by species and infection severity.
- Blood samples are typically drawn just before the next scheduled dose (trough level)
- Levels below 1 microgram/mL may be subtherapeutic
- Levels above 5 micrograms/mL are associated with increased toxicity risk
- TDM is especially critical when switching between species, formulations, or compounding pharmacies
Drug Interactions
- Cisapride — contraindicated due to risk of fatal cardiac arrhythmias
- Other hepatotoxic drugs — increased risk of liver damage
- Cytochrome P-450 inducers (rifampin, phenobarbital) — may dramatically reduce voriconazole levels
- Cytochrome P-450 inhibitors — may increase voriconazole to toxic levels
Avian-Specific Considerations
Birds present unique pharmacological challenges for antifungal therapy:
- Hollow (pneumatic) bones communicate with the air sac system, meaning aspergillosis can invade bone tissue
- Crop anatomy — the crop is a storage organ, not an absorptive surface; drugs must pass to the proventriculus and ventriculus for absorption
- Rapid metabolism — many bird species have high metabolic rates that clear drugs faster than mammals
- Air sac system — the avian respiratory system has no diaphragm and uses a unique flow-through ventilation system with nine air sacs; antifungal drugs must achieve adequate concentration in these poorly vascularized structures
- Nebulization — voriconazole can also be delivered via nebulization to target respiratory tissue directly, often used as an adjunct to systemic therapy
Combination Therapy
Severe aspergillosis cases often require multimodal treatment:
- Systemic voriconazole as the primary antifungal
- Nebulized amphotericin B or terbinafine for direct respiratory tract delivery
- Surgical debridement of accessible granulomas
- Supportive care including thermal support, nutritional support, and treatment of secondary infections
Storage
Store tablets and powder at room temperature, protected from moisture. Compounded oral suspensions should be stored according to the compounding pharmacy’s instructions, typically refrigerated, and used within the specified beyond-use date.
Always consult your avian veterinarian before starting, stopping, or changing any medication. Aspergillosis is a serious, life-threatening condition that requires expert veterinary management. This information is for educational purposes and does not replace professional veterinary advice.